NCT00865462已完成1 期
A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion XL Tablets Formulation in Normal, Healthy Man Following a Standard Meal
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Actavis Inc.
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Rate and Extend of Absorption
研究概览
简要总结
The purpose of this study is to compare the rate and extent of absorption of Abrika Bupropion 150 mg XL Tablet to that of Wellbutrin XL® 150 mg Tablet after a single, one-tablet dose in subjects fed a standard meal.
详细描述
Study Type: Interventional Study Design: Randomized, 2-period, 2-sequence, crossover design.
Official Title: A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion XL Tablets Formulation in Normal, Healthy Man Following a Standard Meal
Further study details as provided by Actavis Elizabeth LLC:
Primary Outcome Measures:
Rate and Extend of Absorption
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Is the individual a healthy, normal adult man who volunteers to participate?
- •Is he 18-45 years of age, inclusive?
- •Is his BMI ≤30?
- •Is he considered reliable and capable of understanding his responsibility and role in the study?
- •Has he provided written informed consent? A no answer to any of the above questions indicates that the individual is ineligible for enrollment
排除标准
- •Does the individual have a history of allergy or hypersensitivity to bupropion, milk or eggs?
- •Does he smoke more than 25 cigarettes/day?
- •Is he unable to refrain from smoking during the period beginning two hours before and ending four hours after study drug administration?
- •Does he have a history of seizure, cranial trauma, or other predisposition to seizure?
- •Does he have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his safety?
- •Does he have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, renal or other diseases, conditions or surgeries that would interfere with the conduct or interpretation of the study or jeopardize his safety?
- •Does he have serious psychological illness?
- •Does he have significant history (within the past six months) or clinical evidence of alcohol or drug abuse?
- •Does he have a positive urine drug screen or saliva alcohol screen, or a positive HIV-l, or hepatitis B or C screen?
- •Is he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 24 and 48 hours, respectively, prior to study drug administration and ending when the last blood sample has been taken?
- •Has he used any prescription drug during the 14-day period prior to study initiation (except for topical products without systemic absorption), or any OTC drug during the 72-hour period preceding study initiation?
- •Is he unable to refrain from the use of all concomitant medications during the study?
- •Has he donated or lost blood, or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six week period preceding study initiation?
- •Has he donated plasma during the two week period preceding study initiation?
- •Has he received an investigational drug during the 30 day period preceding study initiation? A yes answer to any of the above questions indicates that the individual is ineligible for enrollment
研究组 & 干预措施
A
Experimental
Abrika Bupropion 150 mg XL Tablet, single dose
干预措施: Abrika Bupropion 150 mg XL Tablet, single dose (Drug)
B
Active Comparator
Wellbutrin XL® 150 mg Tablet, single dose
干预措施: Wellbutrin XL® 150 mg Tablet, single dose (Drug)
结局指标
主要结局
Rate and Extend of Absorption
时间窗: 96 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed ConditionsHealthyNCT00865371Actavis Inc.26
已完成
1 期
A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting ConditionsHealthyNCT00865111Actavis Inc.26
已完成
1 期
A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting ConditionsHealthyNCT00865410Actavis Inc.26
已完成
1 期
A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting ConditionsHealthyNCT00863941Actavis Inc.28
已完成
1 期
Levetiracetam 1000 mg Under Fasting ConditionsHealthyNCT00859521Teva Pharmaceuticals USA30